Abstract
For men with newly diagnosed prostate cancer, we aimed to develop and validate a model to predict the risk of progression on active surveillance (AS), which could inform more personalised AS strategies. In total, 883 men from 3 European centres were used for model development and internal validation, and 151 men from a fourth European centre were used for external validation. Men with Cambridge Prognostic Group (CPG) 1–2 disease at diagnosis were eligible. The endpoint was progression to the composite endpoint of CPG3 disease or worse (≥CPG3). Model performance at 4 years was evaluated through discrimination (C-index), calibration plots, and decision curve analysis. The final multivariable model incorporated prostate-specific antigen (PSA), Grade Group, magnetic resonance imaging (MRI) score (Prostate Imaging Reporting & Data System (PI-RADS) or Likert), and prostate volume. Calibration and discrimination were good in both internal validation (C-index 0.742, 95% CI 0.694–0.793) and external validation (C-index 0.845, 95% CI 0.712–0.958). In decision curve analysis, the model offered net benefit compared to a ‘follow-all’ strategy at risk thresholds of ≥0.08 and ≥0.04 in development and external validation, respectively. In conclusion, our model demonstrated good accuracy and clinical utility in predicting the progression on AS at 4 years post-diagnosis. Men with lower risk predictions could subsequently be offered less-intense surveillance. Further external validation in larger cohorts is now required.
Reference30 articles.
1. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer;Liu;Urol. Oncol.,2021
2. The Movember Prostate Cancer Landscape Analysis: An assessment of unmet research needs;Kouspou;Nat. Rev. Urol.,2020
3. National Institute for Health and Care Excellence (2022, December 06). Prostate Cancer: Diagnosis and Management. NICE Guidelines [NG131]. Available online: https://www.nice.org.uk/guidance/ng131/chapter/recommendations.
4. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options;Sanda;J. Urol.,2018
5. European Association of Urology (2021, February 12). Prostate Cancer 2020. Available online: https://uroweb.org/guideline/prostate-cancer.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献